• Media
  • Careers
  • Contacts
CBP - Pioneering and developing Bi-targeting XDC technologyCBPCBPCBP

Pioneering and developing Bi-targeting XDC technology

Contacts
  • Who We Are
    • About CBP
    • Our Culture
    • Leadership
    • Our History
  • Science & Innovation
    • Approach
    • Platforms
    • World of Bi-XDC
  • Pipeline
    • Pipeline
    • Clinical Trials
    • Publications
  • For Patient
    • Patient Safety
    • Clinical Sites
    • Expanded Access Policy

Tag Archives: CBP

Author By adminPosted on February 23, 2025February 23, 2025

The U.S. FDA Grants Fast Track Designation to Coherent Biopharma’s CBP-1019

Suzhou, China, February 21, 2025 — Coherent Biopharma (“Coherent”) announced that the U.S. Food and Drug Administration...
Read More
Author By adminPosted on October 12, 2024October 12, 2024

The U.S. FDA Grants Fast Track Designation to Coherent Biopharma’s CBP-1008

October 10, 2024 — Coherent Biopharma (“Coherent”) announced that the U.S. Food and Drug Administration (FDA) has grant...
Read More

Categories

  • News 30

Recent Posts

  • 同宜医药在BioChina发声——以局部给药重塑XDC赛道,打造“改变实践”的创新疗法March 19, 2026
  • Pamplona Therapeutics and CoherentBiopharma Enter Strategic Collaboration to Advance AI-Designed Degrader–Conjugate TherapeuticsMarch 12, 2026
  • 同宜医药与科络思生物达成全面战略合作 携手共推创新药物研发合作与商业化March 9, 2026
  • 超20亿美元!同宜医药全球首款Bi-XDC药物出海,探索前列腺癌治疗新边界December 22, 2025
  • The U.S. FDA Grants Fast Track Designation to Coherent Biopharma’s CBP-1019February 23, 2025

Archives

  • 2026 (3)
  • 2025 (2)
  • 2024 (5)
  • 2023 (6)
  • 2022 (4)
  • 2021 (3)
  • 2020 (4)
  • 2019 (1)
  • 2018 (2)

Meet CBP

  • Leadership
  • Our History
  • Our Culture

Science&Innovation

  • Approach
  • Platforms
  • World of Bi-XDC

Pipeline

  • Pipeline
  • Clinical Trials
  • Publications

For Patient

  • Patient Safety
  • Clinical Sites
  • Expanded Access Policy
Copyright © 2026 CBP  All rights reserved.